Nektar Therapeutics Presents First Preclinical Data On NKTR-0165 For Treatment Of Inflammatory Diseases At EULAR 2024
– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism –
– IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half of 2025 -